Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer
Status:
Active, not recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety of durvalumab (MEDI4736) and tremelimumab in
combination with radiation therapy and find out what effects, if any, this combination has on
people, and whether it improves overall survival.